The fact that knockdown of DDIT3 in CD34+ cells from MDS cases restores erythroid differentiation, suggests that DDIT3 could represent a potential therapeutic target for the treatment of patients, particularly those with anemia. The gene discussed is DDIT3; the disease is myelodysplastic syndrome.